Weatherall, James
Polonsky, William H.
Lanar, Sally
Knoble, Naomi
Håkan-Bloch, Jonas
Constam, Elisabeth
Philis-Tsimikas, Athena
Marrel, Alexia
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 11 September 2017
Accepted: 25 March 2018
First Online: 3 May 2018
Ethics approval and consent to participate
: Central Institutional Review Board approval was obtained for US sites (New England IRB, study #20160797) and Ethics waiver for the site in Switzerland (Kantonale Ethikkommission Zürich, study #2016–00861) and written informed consent was given by all patients.
: Not applicable.
: JW and JHB are or were employed by Novo Nordisk at the time the study was conducted and are share-holders. WHP has served as a consultant for Novo Nordisk, Sanofi and Lilly. SL, NK, and AM are employed by Mapi, which received funding from Novo Nordisk for work performed on this study. EC has no competing interests. APT serves on advisory boards for AstraZeneca, DexCom, Lilly, Novo Nordisk, and Sanofi, and holds stock ownership in Ionis, Radius and Novo Nordisk.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.